Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 03, 2023 10:46 ET
|
Travere Therapeutics, Inc.
“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
October 13, 2023 16:30 ET
|
Travere Therapeutics, Inc.
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for...
OMNIQ’s AI HOMELAND SECURITY SOLUTION SELECTED TO PROTECT ADDITIONAL MIDDLE EASTERN BORDERS
March 29, 2023 08:45 ET
|
OMNIQ Corp.
omniQ’s AI Machine Vision technology identifies patterns and enable proactive smart decisionsomniQ’s AI Homeland Security solutions are already deployed in foreign Ministry of Defense Head Quarters,...
Passive Fire Protection Market Value Predicted To Reach US$ 5,263.7 Million By 2027: Acumen Research And Consulting
April 16, 2021 11:12 ET
|
Acumen Research and Consulting
LOS ANGELES, April 16, 2021 (GLOBE NEWSWIRE) -- The Global Passive Fire Protection Market is expected to grow at a CAGR of around 6.8% from 2020 to 2027 and reach the market value of over US$...
FallSafety Launches Emergency Check-Ins to Protect Enterprise Employees
March 15, 2021 08:00 ET
|
Tidyware
FallSafety launches enterprise-grade emergency check-insEmergency check-ins help protect company employees during crisisWorker protection for severe weather, social dangers, and other potentially...
Bel to Present at the Q1 Virtual Investor Summit
March 11, 2021 07:15 ET
|
BEL FUSE INC.
JERSEY CITY, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Bel BELFB today announced that Lynn Hutkin (Director of Financial Reporting), Farouq Tuweiq (CFO), Pete Bittner (President,...
ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp
March 04, 2021 08:32 ET
|
Arch Biopartners
TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett,...
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
September 21, 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
June 16, 2019 12:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 01, 2019 08:00 ET
|
VBI Vaccines, Inc.
All four lead pipeline programs progressing towards expected clinical milestones in 2019Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine,...